Roots Analysis
JANUARY 23, 2024
The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.
The Pharma Data
AUGUST 20, 2020
Among the drugs to lose contracts were Eli Lilly schizophrenia medicine Zyprexa and Pfizer’s Viagra, the publication said. It has since expanded nationwide, threatening an important market for many Big Pharma players. . RELATED: Is Pfizer’s established drugs’ decline in China the ‘canary in the coalmine?’
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
The Pharma Data
DECEMBER 31, 2020
Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector.
Roots Analysis
OCTOBER 12, 2023
Strategic Relationships: This parameter represents the strategic alliances, partners, or a burgeoning customer base in order to evaluate the marketing risks of a start-up. As a senior analyst at Roots Analysis, Gaurav has assisted several clients across multiple industry verticals within the healthcare domain. Gaurav holds a B.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Expert insights. Personalized for you.
40 
Let's personalize your content